225 related articles for article (PubMed ID: 34655242)
41. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
42. Phosphokinome Analysis of Barth Syndrome Lymphoblasts Identify Novel Targets in the Pathophysiology of the Disease.
Agarwal P; Cole LK; Chandrakumar A; Hauff KD; Ravandi A; Dolinsky VW; Hatch GM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002286
[TBL] [Abstract][Full Text] [Related]
43. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.
Garlid AO; Schaffer CT; Kim J; Bhatt H; Guevara-Gonzalez V; Ping P
Gene; 2020 Feb; 726():144148. PubMed ID: 31647997
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of branched-chain amino acid aminotransferases rescues the growth defects of cells lacking the Barth syndrome-related gene TAZ1.
Antunes D; Chowdhury A; Aich A; Saladi S; Harpaz N; Stahl M; Schuldiner M; Herrmann JM; Rehling P; Rapaport D
J Mol Med (Berl); 2019 Feb; 97(2):269-279. PubMed ID: 30604168
[TBL] [Abstract][Full Text] [Related]
45. Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes.
Aryal B; Rao VA
PLoS One; 2016; 11(7):e0158376. PubMed ID: 27434059
[TBL] [Abstract][Full Text] [Related]
46. The Role of Cardiolipin in Cardiovascular Health.
Shen Z; Ye C; McCain K; Greenberg ML
Biomed Res Int; 2015; 2015():891707. PubMed ID: 26301254
[TBL] [Abstract][Full Text] [Related]
47. Defective Mitochondrial Cardiolipin Remodeling Dampens HIF-1α Expression in Hypoxia.
Chowdhury A; Aich A; Jain G; Wozny K; Lüchtenborg C; Hartmann M; Bernhard O; Balleiniger M; Alfar EA; Zieseniss A; Toischer K; Guan K; Rizzoli SO; Brügger B; Fischer A; Katschinski DM; Rehling P; Dudek J
Cell Rep; 2018 Oct; 25(3):561-570.e6. PubMed ID: 30332638
[TBL] [Abstract][Full Text] [Related]
48. FGF21 and GDF15 are elevated in Barth Syndrome and are correlated to important clinical measures.
Liu O; Chinni BK; Manlhiot C; Vernon HJ
Mol Genet Metab; 2023 Nov; 140(3):107676. PubMed ID: 37549445
[TBL] [Abstract][Full Text] [Related]
49. Metabolic switch from fatty acid oxidation to glycolysis in knock-in mouse model of Barth syndrome.
Chowdhury A; Boshnakovska A; Aich A; Methi A; Vergel Leon AM; Silbern I; Lüchtenborg C; Cyganek L; Prochazka J; Sedlacek R; Lindovsky J; Wachs D; Nichtova Z; Zudova D; Koubkova G; Fischer A; Urlaub H; Brügger B; Katschinski DM; Dudek J; Rehling P
EMBO Mol Med; 2023 Sep; 15(9):e17399. PubMed ID: 37533404
[TBL] [Abstract][Full Text] [Related]
50. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.
Hsu P; Liu X; Zhang J; Wang HG; Ye JM; Shi Y
Autophagy; 2015 Apr; 11(4):643-52. PubMed ID: 25919711
[TBL] [Abstract][Full Text] [Related]
51. Defining functional classes of Barth syndrome mutation in humans.
Lu YW; Galbraith L; Herndon JD; Lu YL; Pras-Raves M; Vervaart M; Van Kampen A; Luyf A; Koehler CM; McCaffery JM; Gottlieb E; Vaz FM; Claypool SM
Hum Mol Genet; 2016 May; 25(9):1754-70. PubMed ID: 26908608
[TBL] [Abstract][Full Text] [Related]
52. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
Schlame M; Xu Y
J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
[TBL] [Abstract][Full Text] [Related]
53. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.
Soustek MS; Falk DJ; Mah CS; Toth MJ; Schlame M; Lewin AS; Byrne BJ
Hum Gene Ther; 2011 Jul; 22(7):865-71. PubMed ID: 21091282
[TBL] [Abstract][Full Text] [Related]
54. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
Sabbah HN; Taylor C; Vernon HJ
Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
[TBL] [Abstract][Full Text] [Related]
55. Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.
Bowron A; Honeychurch J; Williams M; Tsai-Goodman B; Clayton N; Jones L; Shortland GJ; Qureshi SA; Heales SJ; Steward CG
J Inherit Metab Dis; 2015 Mar; 38(2):279-86. PubMed ID: 25112388
[TBL] [Abstract][Full Text] [Related]
56. Barth syndrome and the many fascinating aspects of cardiolipin.
Vaz FM; Wanders RJA; Vernon H
J Inherit Metab Dis; 2022 Jan; 45(1):1-2. PubMed ID: 34855207
[No Abstract] [Full Text] [Related]
57. The enigmatic role of tafazzin in cardiolipin metabolism.
Houtkooper RH; Turkenburg M; Poll-The BT; Karall D; Pérez-Cerdá C; Morrone A; Malvagia S; Wanders RJ; Kulik W; Vaz FM
Biochim Biophys Acta; 2009 Oct; 1788(10):2003-14. PubMed ID: 19619503
[TBL] [Abstract][Full Text] [Related]
58. Current Knowledge on the Role of Cardiolipin Remodeling in the Context of Lipid Oxidation and Barth Syndrome.
Liang Z; Schmidtke MW; Greenberg ML
Front Mol Biosci; 2022; 9():915301. PubMed ID: 35693555
[TBL] [Abstract][Full Text] [Related]
59. Cellular functions of cardiolipin in yeast.
Joshi AS; Zhou J; Gohil VM; Chen S; Greenberg ML
Biochim Biophys Acta; 2009 Jan; 1793(1):212-8. PubMed ID: 18725250
[TBL] [Abstract][Full Text] [Related]
60. Cardiolipin fingerprinting of leukocytes by MALDI-TOF/MS as a screening tool for Barth syndrome.
Angelini R; Lobasso S; Gorgoglione R; Bowron A; Steward CG; Corcelli A
J Lipid Res; 2015 Sep; 56(9):1787-94. PubMed ID: 26144817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
